Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN5381 in uncontrolled hypertension
NCT06833190Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2025
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of REGN5381 in hypertension (HTN), sponsored by Regeneron Pharmaceuticals. Started Apr 2025; status: terminated.
02
Drugs
REGN5381
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06833190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06833190.